Spinelli, Orietta <br/><br/>
Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.  [electronic resource] 

 -  Haematologica  May 2007 
 - 612-8 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1592-8721 
<br/><br/><label>Standard No.: </label>10.3324/haematol.10965  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Basic Helix-Loop-Helix Transcription Factors--genetics<br/>Benzamides<br/>Biomarkers, Tumor--blood<br/>Clinical Trials as Topic--statistics & numerical data<br/>Cohort Studies<br/>Combined Modality Therapy<br/>Female<br/>Fusion Proteins, bcr-abl--blood<br/>Gene Deletion<br/>Gene Rearrangement, B-Lymphocyte<br/>Gene Rearrangement, T-Lymphocyte<br/>Hematopoietic Stem Cell Transplantation<br/>Humans<br/>Imatinib Mesylate<br/>Kaplan-Meier Estimate<br/>Kinetics<br/>Leukemia-Lymphoma, Adult T-Cell--blood<br/>Male<br/>Middle Aged<br/>Multicenter Studies as Topic<br/>Myeloid-Lymphoid Leukemia Protein--blood<br/>Neoplasm, Residual<br/>Oncogene Proteins, Fusion--blood<br/>Piperazines--administration & dosage<br/>Polymerase Chain Reaction<br/>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma--blood<br/>Precursor Cell Lymphoblastic Leukemia-Lymphoma--blood<br/>Proto-Oncogene Proteins--genetics<br/>Pyrimidines--administration & dosage<br/>Remission Induction<br/>Risk<br/>Survival Analysis<br/>Survival Rate<br/>T-Cell Acute Lymphocytic Leukemia Protein 1<br/>Translocation, Genetic<br/>Transplantation Conditioning<br/>Transplantation, Homologous<br/>Treatment Outcome